Evidence map›Paper›PMID 31388861›Full record

SynthesisTechniques in coloproctology2019

Individual participant data pooled-analysis of risk factors for recurrence after neoadjuvant radiotherapy and transanal local excision of rectal cancer: the PARTTLE study.

A Arezzo, G Lo Secco, R Passera, L Esposito, M Guerrieri, M Ortenzi, K Bujko, R O Perez, A Habr-Gama, F Stipa and 7 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Techniques in coloproctology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The Crying Need for a Better Response Assessment in Rectal Cancer.Current treatment options in oncology · 2023
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

A ArezzoDepartment of Surgical Sciences, University of Torino, Corso Dogliotti 14, 10126, Turin, Italy. alberto.arezzo@unito.it.
G Lo SeccoDepartment of Surgical Sciences, University of Torino, Corso Dogliotti 14, 10126, Turin, Italy.
R PasseraDepartment of Nuclear Medicine, San Giovanni Battista Hospital, University of Turin, Turin, Italy.
L EspositoDepartment of Surgical Sciences, University of Torino, Corso Dogliotti 14, 10126, Turin, Italy.
M GuerrieriDepartment of General Surgery, Università Politecnica delle Marche, Ancona, Italy.
M OrtenziDepartment of General Surgery, Università Politecnica delle Marche, Ancona, Italy.
K BujkoDepartment of Radiotherapy, Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland.
R O PerezColorectal Surgery Division, University of São Paulo School of Medicine, São Paulo, Brazil.
A Habr-GamaColorectal Surgery Division, University of São Paulo School of Medicine, São Paulo, Brazil.
F StipaDepartment of Surgery, Azienda Ospedaliera San Giovanni-Addolorata, Rome, Italy.
M PicchioDepartment of Surgery, Azienda Ospedaliera San Giovanni-Addolorata, Rome, Italy.
A RestivoDepartment of Surgical Sciences, University of Cagliari, Cagliari, Italy.
L ZorcoloDepartment of Surgical Sciences, University of Cagliari, Cagliari, Italy.
C CocoDepartment of Surgical Sciences, Catholic University of Sacred Heart, Rome, Italy.
G RizzoDepartment of Surgical Sciences, Catholic University of Sacred Heart, Rome, Italy.
M MistrangeloDepartment of Surgical Sciences, University of Torino, Corso Dogliotti 14, 10126, Turin, Italy.
M MorinoDepartment of Surgical Sciences, University of Torino, Corso Dogliotti 14, 10126, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn organ-preserving strategy may be a valid alternative in the treatment of selected patients with rectal cancer after neoadjuvant radiotherapy. Preoperative assessment of the risk for tumor recurrence is a key component of surgical planning. The aim of the present study was to increase the current knowledge on the risk factors for tumor recurrence.

methodsThe present study included individual participant data of published studies on rectal cancer surgery. The literature was reviewed according to according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Individual Participant Data checklist (PRISMA-IPD) guidelines. Series of patients, whose data were collected prospectively, having neoadjuvant radiotherapy followed by transanal local excision for rectal cancer were reviewed. Three independent series of univariate/multivariate binary logistic regression models were estimated for the risk of local, systemic and overall recurrence, respectively.

resultsWe identified 15 studies, and 7 centers provided individual data on 517 patients. The multivariate analysis showed higher local and overall recurrences for ypT3 stage (OR 4.79; 95% CI 2.25-10.16 and OR 6.43 95% CI 3.33-12.42), tumor size after radiotherapy > 10 mm (OR 5.86 95% CI 2.33-14.74 and OR 3.14 95% CI 1.68-5.87), and lack of combined chemotherapy (OR 3.68 95% CI 1.78-7.62 and OR 2.09 95% CI 1.10-3.97), while ypT3 was the only factor correlated with systemic recurrence (OR 5.93). The analysis of survival curves shows that the overall survival is associated with ypT and not with cT.

conclusionsLocal excision should be offered with caution after neoadjuvant chemoradiotherapy to selected patients with rectal cancers, who achieved a good response to neoadjuvant chemoradiotherapy.

Indexed as

AgedDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingPostoperative PeriodProctectomyRadiotherapy, AdjuvantRectal NeoplasmsRisk FactorsTransanal Endoscopic SurgeryTreatment OutcomeLocal neoplasm recurrenceNeoadjuvant treatmentRadiotherapyRectal cancerTransanal endoscopic microsurgery

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.